Navigation Links
ESRC offers new dynamics for old in UK

By 2025, the number of people in Britain over the age of 60 will outnumber those under 25. Pressure on both pensions and pensioner spending power will increase. Answers to problems//, old and new, will have to be sought.

In a move to address the issues of ageing - one of the most significant aspects of change in our lives, the Economic and Social Research Council (ESRC) is highlighting the impact of ageing on society, and offering expanded research funding to provide leading edge thinking in this highly relevant area.

Professor Ian Diamond, CEO of the ESRC says: "As a key part of our Strategic Plan, over the next two years, ESRC will spend over £2.5 million funding ageing research - in addition to our continuing responsive-mode research portfolio worth a further £2 million. We are confident that Britain's leading social-scientists will target such resources for innovative research into the challenges of ageing and understand the changes to society that will affect all our lives."

ESRC funded research has featured through the Institute for Fiscal Studies (IFS), which hosts the Centre for Microeconomic Analysis of Public Policy directed by Professor Richard Blundell of University College London alongside Professor James Banks, Director of the Centre for Economic Research on Ageing at the IFS. "Prepared for Retirement?" - new work from the IFS on the adequacy and distribution of retirement resources, has researched future wealth patterns amongst the retired, and provisions that they may make.

The report highlights that government and private pensions needs are changing, and that for the first time, retirees face less pension provisions than their predecessors; changes to working patterns will affect the balance of labour supply and labour demand amongst both young and old. The life course of the elderly changes as they work longer, contribute more to the economy, and have a wider role in the family amid increasing life expe
'"/>




Page: 1 2 3

Related medicine news :

1. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Magnesium sulfate offers no help in migraine treatment
4. Roche offers HIV drug expertise to poor nations
5. Genetically modified Lactic acid bacteria offers HIV protection
6. SRL Ranbaxy offers quicker bird flu diagnostic test
7. Victorian Initiative: Coffers Are Ringing For an Upcoming Cancer Agency
8. Kidney Disease Is Milking the Government Coffers - Is Australia Notorious for High Rates of Kidney Disease?
9. Transporter offers reliable clues for safer pain medicine
10. Fermented Milk offers protection against allergies in infants
11. Tegaserod offers relief for Chronic Constipation
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ESRC offers new dynamics for old

(Date:7/25/2008)...alif., July 25 /PRNewswire/ -- AutoGenomics, Inc. ...tatement on Form S-1 with the,Securities and Excha...blic,offering of shares of its common stock. The n... of which are expected to be offered by,AutoGenomi...ve not yet been,determined., J.P. Morgan Securiti...
(Date:7/25/2008)... The Retina Group of New York will prese...cular degeneration especially designed for seniors...ic Library at 116 Merritts Road, Farmingdale, NY 1...ndance is free and refreshments will be provided. ...-6100. , Hicksville and H...
(Date:7/25/2008)... Columbus-based law firm represents Pick...ef purchased at Columbus-area Kroger store , ...uly 25, 2008 -- http://www.donaheyohioinjurylawye... personal injury law firms in central Ohio, has fi... Court (Case No. 08CV9804) against The Kroger Co.,...
(Date:7/24/2008)...inn., July 24 /PRNewswire-FirstCall/ -- ev3 Inc. (...port its 2008 second quarter and,year-to-date fina... quarter,and year-to-date financial results on Mon...ours., The company will host a conference call an...tern Time) on Tuesday, July 29, 2008. ev3,manageme...
Breaking Medicine News(10 mins):Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Donahey Law Firm Files E. Coli Product Liability Lawsuit Against Kroger Company in Franklin County Court 2Health News:ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call 2
...eatment given to people bitten by snakes or dogs. ...ission//. Africa, Latin America and Asia are the ...bite and scorpion stings. When it comes to snake b...wn as many of them prefer home remedies to hospita...
...sease. Yet recent studies have shown that the chan...es such as diet and exercise//, the chances of sur...rld Cancer Research Fund is putting around 50,000 ...ried out by Dundee University, Scotland. The thre...
In Search of Truth - 'Lie Detector
... women’s hospital in Vancouver, Canada last weeken...bies have a fair chance of survival//. Parents o...e infants and making them breathe on their own are...ctors now. Each of these babies weighed around 1...
Other Medicine News:Health News:In Search of Truth - 'Lie Detector 2Health News:In Search of Truth - 'Lie Detector 3Health News:In Search of Truth - 'Lie Detector 4
(Date:7/23/2008)...Body Have Greater Concentrations of,Stem Cells, A...wire/ -- Fat removed,from the lower abdomen and in...xcellent source of stem cells, with higher stem ce...ports a Brazilian-based study in August,s,Plastic ...l journal of the,American Society of Plastic Surge...
(Date:7/23/2008)...all/ -- Dendreon Corporation,(Nasdaq: DNDN ) toda...onitoring Committee (IDMC) to review in October 20...ng to the Company,s Phase 3 IMPACT (IMmunotherapy,...as D9902B) clinical trial,of PROVENGE(R) (sipuleuc...ctive cellular immunotherapy for the treatment of ...
(Date:7/22/2008)...swire-FirstCall/ -- Following a,thorough review th...harmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) to...hase 3 study in liver cancer. Progen confirmed,its...olio of compounds and,the company will actively se...es through Merger & Acquisition activity., The st...
(Date:7/22/2008)...- Nonin Medical, a leading innovator,of physiologi...as entered,the clinical testing phase with its bre...turation. Today,s most common application for this...gional blood oxygenation,in the brain -- cerebral ...n ongoing clinical study at the,Duke University Me...
Breaking Medicine Technology:Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Is Tap Water Safe for Your Dog 3F 20799 1Is Tap Water Safe for Your Dog 3F 20799 2Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine 28R 29 28VNP40101M 29 and Cytarabine in Relapsed Acute Myelog 20797 1Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine 28R 29 28VNP40101M 29 and Cytarabine in Relapsed Acute Myelog 20797 2Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine 28R 29 28VNP40101M 29 and Cytarabine in Relapsed Acute Myelog 20797 3Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine 28R 29 28VNP40101M 29 and Cytarabine in Relapsed Acute Myelog 20797 4Mylan Inc Acquires Central Eastern European Generics Businesses of Merck KGaA 20795 1Mylan Inc Acquires Central Eastern European Generics Businesses of Merck KGaA 20795 2IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 1IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 2IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 3IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 4IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 5
...wire/ -- Results from,the primary analysis of a ra...owed that 77 percent of treatment-experienced HIV-...600 mg tablets with,100 mg ritonavir (PREZISTA/r) ...(OBR) of antiretroviral (ARV) agents, reached a,pl...ared to 68,percent of patients taking Kaletra(R)1 ...
...ire-FirstCall/ --,Genzyme Corp. announced top-line... studies to assess the safety and efficacy of,tole...polymer,therapy for patients with Clostridium diff... 3 study of tolevamer liquid is fully,enrolled and...irst Phase 3 study known as the Polymer Alternativ...
Other Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 2Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 3Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 4
Aaron manufactures two groups of flexible lighting products. The first is available both sterile and non-sterile in three different sizes 5", 10", and 15" (refers to the flexible shaft portion of the
Designed to be used for neuromuscular blockage monitoring. Provides for easy placement over the ulnar nerve on a patient's wrist. Dual element permits non-invasive monitoring using a single electrode
...ch maintains power to the instrument without gener..., Tetanus: 100 Hz (200 pulses/s) , Train-Of-Four: ... from 0-70 mA , Stimulus Pulse: Square Wave Monop...ry LED (green) indicates that the units on; it fla...
...tor from B. Braun Medical. It has set the pace for...r 10 years. , ,NEW! Remote Control Unit. Now avai...current output control device for your Stimuplex D...lo to raise and lower current output from the Stim...
Medicine Products: